A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

OBJECTIVE: In disease‐modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinblatt, Michael E., Bingham, Clifton O., Burmester, Gerd‐Rüdiger, Bykerk, Vivian P., Furst, Daniel E., Mariette, Xavier, van der Heijde, Désirée, van Vollenhoven, Ronald, VanLunen, Brenda, Ecoffet, Cécile, Cioffi, Christopher, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656933/
https://www.ncbi.nlm.nih.gov/pubmed/28666080
http://dx.doi.org/10.1002/art.40196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656933/
https://www.ncbi.nlm.nih.gov/pubmed/28666080
http://dx.doi.org/10.1002/art.40196

Ejemplares similares